120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
乳腺癌内脏转移中的受体不一致性和分子亚型变化
Authors Tian Z , Chen X, Li H, Li C, Qiu W, Wang X , Song X, Hou B, Liu Z, Yu J , Yu Z
Received 25 September 2025
Accepted for publication 16 January 2026
Published 23 January 2026 Volume 2026:18 565375
DOI https://doi.org/10.2147/BCTT.S565375
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Pranela Rameshwar
Zhaokun Tian,1,2,* Xiaojie Chen,1,2,* Haojia Li,2,* Chao Li,2 Wenyan Qiu,1,2 Xinzhao Wang,2 Xiang Song,2 Boyang Hou,2 Zhaoyun Liu,2 Jinming Yu,1,2 Zhiyong Yu1,2
1First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, People’s Republic of China; 2Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jinming Yu, Email sdyujinming@163.com Zhiyong Yu, Email drzhiyongyu@aliyun.com
Background: Visceral metastases in breast cancer demonstrate considerable molecular heterogeneity. This study examines changes in receptor status and molecular subtypes between primary breast cancer and visceral metastases.
Methods: A retrospective analysis was conducted on 430 patients diagnosed with breast cancer and visceral metastases, including 138 with lung metastases and 292 with liver metastases. Receptor statuses (estrogen receptor [ER], progesterone receptor [PR], human epidermal growth factor receptor 2 [HER2]) were assessed in both primary and metastatic tumors. Discordance in molecular subtypes was assessed, and factors influencing receptor changes were identified. Survival outcomes were estimated using Kaplan–Meier analysis.
Results: Receptor discordance was observed in 47.9% (206/430) of patients, with a higher frequency in liver metastases (51.0%) than in lung metastases (41.3%). PR discordance was the most frequent (36.2%), followed by ER (18.9%) and HER2 (7.2%). Molecular subtype discordance occurred in 36.1% of patients, with the highest rate in Luminal A tumors (85.7%). Multivariate analysis identified pN3 stage and molecular subtype as independent predictors. Kaplan–Meier survival analysis showed that patients with ER gain had significantly improved disease-free survival (DFS) compared with those with ER loss (75.4 vs 44.5 months, P = 0.0092). Moreover, molecular subtype discordance was associated with longer DFS (63.9 vs 49.1 months, P = 0.0079).
Conclusion: This study emphasizes that there are significant differences in receptor expression and molecular subtypes between primary breast tumors and their visceral metastases. The receptor is more likely to change in patients with liver metastasis and Luminal A or Luminal B (HER2+) tumors, highlighting the importance of repeat biopsy in the metastatic environment. These findings can be used to identify high-risk patients and provide them with better treatment plans.
Keywords: breast cancer, receptor discordance, molecular subtype, visceral metastasis, survival analysis
1First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, People’s Republic of China; 2Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jinming Yu, Email sdyujinming@163.com Zhiyong Yu, Email drzhiyongyu@aliyun.com
Background: Visceral metastases in breast cancer demonstrate considerable molecular heterogeneity. This study examines changes in receptor status and molecular subtypes between primary breast cancer and visceral metastases.
Methods: A retrospective analysis was conducted on 430 patients diagnosed with breast cancer and visceral metastases, including 138 with lung metastases and 292 with liver metastases. Receptor statuses (estrogen receptor [ER], progesterone receptor [PR], human epidermal growth factor receptor 2 [HER2]) were assessed in both primary and metastatic tumors. Discordance in molecular subtypes was assessed, and factors influencing receptor changes were identified. Survival outcomes were estimated using Kaplan–Meier analysis.
Results: Receptor discordance was observed in 47.9% (206/430) of patients, with a higher frequency in liver metastases (51.0%) than in lung metastases (41.3%). PR discordance was the most frequent (36.2%), followed by ER (18.9%) and HER2 (7.2%). Molecular subtype discordance occurred in 36.1% of patients, with the highest rate in Luminal A tumors (85.7%). Multivariate analysis identified pN3 stage and molecular subtype as independent predictors. Kaplan–Meier survival analysis showed that patients with ER gain had significantly improved disease-free survival (DFS) compared with those with ER loss (75.4 vs 44.5 months, P = 0.0092). Moreover, molecular subtype discordance was associated with longer DFS (63.9 vs 49.1 months, P = 0.0079).
Conclusion: This study emphasizes that there are significant differences in receptor expression and molecular subtypes between primary breast tumors and their visceral metastases. The receptor is more likely to change in patients with liver metastasis and Luminal A or Luminal B (HER2+) tumors, highlighting the importance of repeat biopsy in the metastatic environment. These findings can be used to identify high-risk patients and provide them with better treatment plans.
Keywords: breast cancer, receptor discordance, molecular subtype, visceral metastasis, survival analysis